Baloxavir Marboxil
A prodrug of baloxavir, which inhibits the cap-dependent endonuclease enzyme that influenza viruses need to copy their genetic material, stopping replication of both influenza A and B viruses. A single oral dose can shorten the duration of influenza illness.
Khối lượng phân tử
571,6000 g/mol
LogP
3,80
TPSA
123,00 Ų
Lipinski RO5
Không đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O
InChI
InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
Molecular Formula
C27H23F2N3O7S
HBD / HBA
- / 12
Liên kết có thể quay
6
Nguyên tử nặng
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A prodrug of baloxavir, which inhibits the cap-dependent endonuclease enzyme that influenza viruses need to copy their genetic material, stopping replication of both influenza A and B viruses. A single oral dose can shorten the duration of influenza illness.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Baloxavir Marboxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297503. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 124081896. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="baloxavir-marboxil"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/baloxavir-marboxil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/baloxavir-marboxil/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/baloxavir-marboxil/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="baloxavir-marboxil"></drugfyi-drug>